Mounjaro Side Effects Cancer UK | Safety Guide 2024

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro Side Effects Cancer - UK Price £124.99

Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off first order using code WEIGHTLOSSNEW

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman starting a weight loss consultation on the Cured Pharmacy website

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Your Mounjaro Side Effects Cancer Questions Answered

Published on: June 03, 2026

Concerns about mounjaro side effects cancer UK are among the most common questions we receive at Cured Pharmacy. As a UK-registered pharmacy with a clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), we understand the importance of evidence-based answers when considering weight loss treatment. This guide addresses the current scientific evidence on tirzepatide and cancer risk, helping you make an informed decision about your health.

Understanding Mounjaro Side Effects Cancer Research

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. When patients ask about mounjaro side effects cancer concerns, they're typically referring to warnings about medullary thyroid carcinoma (MTC) that appear on GLP-1 receptor agonist medications.

The thyroid cancer warning stems from animal studies where rodents developed thyroid C-cell tumours when exposed to GLP-1 receptor agonists at doses far exceeding human therapeutic levels [2]. However, it's crucial to understand that human thyroid C-cells have significantly fewer GLP-1 receptors than rodent C-cells, making direct extrapolation problematic.

In clinical trials involving over 5,000 patients across the SURPASS programme, no cases of medullary thyroid carcinoma were reported in tirzepatide-treated participants [1]. The average follow-up period extended to 72 weeks, providing substantial safety data. Whilst this doesn't eliminate theoretical risk entirely, it offers reassuring evidence for patients considering treatment.

Does Mounjaro Cause Cancer? Clinical Trial Evidence

The question 'does mounjaro cause cancer' requires careful examination of both preclinical and clinical data. Across the comprehensive SURPASS clinical trial programme, which included SURPASS-1 through SURPASS-5, researchers monitored participants for adverse events including malignancies [1][3].

Cancer incidence rates in tirzepatide-treated patients were consistent with background population rates and showed no significant difference compared to placebo or active comparator groups [3]. The most extensive trial, SURPASS-4, followed patients with type 2 diabetes for up to 104 weeks and reported malignancy rates of approximately 0.6% in the tirzepatide group versus 0.4% in the glargine insulin group—a difference not considered statistically significant.

Post-marketing surveillance data from the United States, where tirzepatide has been available since 2022, has not identified any concerning cancer signals. The MHRA and European Medicines Agency continue active pharmacovigilance monitoring, and no regulatory warnings regarding general cancer risk have been issued beyond the standard thyroid precautions.

Contraindications Related to Thyroid Cancer

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. During your clinical assessment at Cured Pharmacy, our UK prescribers will specifically screen for these conditions before approving treatment. If you have any personal or family history of thyroid cancer, you must disclose this information during your consultation, as alternative weight loss treatments may be more appropriate.

Mounjaro Thyroid Cancer Risk UK: What You Need to Know

The mounjaro thyroid cancer risk UK concern centres specifically on medullary thyroid carcinoma, a rare form accounting for approximately 3-4% of all thyroid cancers in the UK [4]. MTC arises from parafollicular C-cells in the thyroid gland, which produce calcitonin rather than thyroid hormone.

UK prescribers are required to counsel patients about the theoretical thyroid cancer risk before initiating GLP-1 receptor agonist therapy. However, it's important to contextualise this risk: MTC is exceptionally rare, with an annual incidence of approximately 0.2 cases per 100,000 people in the UK. No causal relationship between tirzepatide and MTC has been established in humans.

If you experience symptoms such as a lump in your neck, persistent hoarseness, difficulty swallowing, or shortness of breath whilst taking Mounjaro, you should contact your GP immediately. These symptoms warrant investigation regardless of medication use, as they may indicate various thyroid conditions requiring clinical assessment.

Monitoring and Safety Protocols

Routine calcitonin screening or thyroid ultrasound monitoring is not recommended for patients taking tirzepatide, as per MHRA and NICE guidance. Such screening has not been shown to improve outcomes and may lead to unnecessary interventions due to false-positive results. Your UK prescriber will instead focus on clinical assessment of symptoms and regular review of your treatment response and tolerability.

Treatment Active Ingredient Administration Starting Price
Mounjaro Tirzepatide Weekly injection From £124.99
Wegovy Semaglutide Weekly injection From £69.00
Saxenda Liraglutide Daily injection From £68.00
Orlistat Orlistat 120mg Three times daily capsule From £32.00
Xenical Orlistat 120mg Three times daily capsule From £32.00

Tirzepatide Cancer Side Effects: Beyond Thyroid Concerns

When discussing tirzepatide cancer side effects, it's worth examining whether GLP-1 receptor agonists might influence other cancer types. Some research has explored potential protective effects of these medications against certain obesity-related malignancies, given their significant impact on weight reduction and metabolic health [5].

Obesity itself is an established risk factor for at least 13 different cancer types, including breast, colorectal, endometrial, oesophageal, kidney, and pancreatic cancers. The substantial weight loss achieved with tirzepatide—averaging 15-22.5% of body weight in clinical trials—may theoretically reduce long-term cancer risk by addressing this fundamental risk factor [1].

Observational studies of other GLP-1 receptor agonists have suggested possible reductions in certain obesity-related cancers, though these findings require confirmation through dedicated long-term studies. The SURPASS trials were not specifically designed to assess cancer outcomes, so definitive conclusions about cancer prevention cannot be drawn from existing data.

Mounjaro Safety Profile UK: Common vs Serious Side Effects

Whilst cancer concerns receive significant attention, the most common mounjaro side effects UK patients actually experience are gastrointestinal in nature. In clinical trials, nausea occurred in 12-22% of patients, diarrhoea in 13-16%, and vomiting in 6-10%, with rates varying by dose [1]. These effects typically diminish over the first 4-8 weeks of treatment.

Serious adverse events occurred in approximately 6.2% of tirzepatide-treated patients in the SURPASS trials, compared to 7.1% in placebo groups [3]. The most clinically significant risks include hypoglycaemia (particularly when combined with insulin or sulphonylureas), acute pancreatitis (occurring in approximately 0.2% of patients), and gallbladder disorders including cholelithiasis.

At Cured Pharmacy, our UK clinical team reviews your full medical history during the online consultation to identify any contraindications or risk factors. Patients with a history of pancreatitis, severe gastroparesis, or inflammatory bowel disease require particularly careful assessment before tirzepatide can be prescribed. All prescription medications dispensed through our pharmacy are subject to approval by a UK-registered prescriber.

When to Seek Medical Attention

You should contact your GP or NHS 111 immediately if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to the back), or symptoms of gallbladder disease (right upper abdominal pain, particularly after eating). Whilst these events are uncommon, prompt medical assessment ensures appropriate management if they occur.

Mounjaro Long Term Side Effects Cancer: Current Evidence

Questions about mounjaro long term side effects cancer reflect understandable concerns given the medication's relatively recent approval. Tirzepatide received UK marketing authorisation in September 2023 for weight management, meaning long-term real-world data beyond the 72-104 week clinical trial periods is still accumulating [1].

The MHRA maintains active post-marketing surveillance through the Yellow Card scheme, where healthcare professionals and patients can report suspected adverse reactions. As of early 2024, no concerning cancer signals have emerged from this pharmacovigilance data. Long-term extension studies of the SURPASS trials are ongoing, with some participants followed for up to 3-4 years.

It's worth noting that semaglutide, a related GLP-1 receptor agonist, has been available since 2018 for diabetes and 2021 for weight management, providing a longer safety track record for this medication class. Comprehensive analyses of semaglutide safety data have not identified increased cancer risk, offering some reassurance about the broader GLP-1 class [2]. However, each medication must be evaluated on its own evidence base.

Ongoing Research and Monitoring

Pharmaceutical manufacturers are required to conduct post-authorisation safety studies as a condition of MHRA approval. For tirzepatide, these include long-term cardiovascular outcome trials and extended safety monitoring. UK prescribers and pharmacies like Cured Pharmacy participate in this surveillance by reporting adverse events and maintaining detailed treatment records. Patients prescribed Mounjaro contribute to this safety knowledge base, helping future patients make informed decisions.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  3. Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., & Wiese, R. J. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet, 398(10313), 1811–1824. https://doi.org/10.1016/S0140-6736(21)02188-7 [accessed 13 August 2026]
  4. Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016). Thyroid cancer. The Lancet, 388(10061), 2783–2795. https://doi.org/10.1016/S0140-6736(16)30172-6 [accessed 13 August 2026]
  5. Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016). Body Fatness and Cancer — Viewpoint of the IARC Working Group. New England Journal of Medicine, 375(8), 794–798. https://doi.org/10.1056/NEJMsr1606602 [accessed 13 August 2026]
  6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Does Mounjaro cause cancer in humans?
Current clinical trial data involving over 5,000 patients shows no evidence that Mounjaro causes cancer in humans. Thyroid cancer warnings are based on rodent studies and have not been observed in human trials or post-marketing surveillance.
What is the thyroid cancer warning on Mounjaro?
Mounjaro carries a warning about medullary thyroid carcinoma (MTC) based on animal studies, and is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. No cases of MTC have been reported in human clinical trials.
Should I be screened for thyroid cancer before starting Mounjaro?
Routine calcitonin testing or thyroid ultrasound screening is not recommended by UK guidelines. Your prescriber will take a thorough medical history to identify any personal or family history of medullary thyroid carcinoma, which would contraindicate treatment.
Are there other cancer risks with Mounjaro besides thyroid cancer?
Clinical trials have not identified increased risk of other cancer types with tirzepatide. Cancer incidence rates in Mounjaro-treated patients were consistent with background population rates across all SURPASS trials.
How long has Mounjaro been studied for cancer side effects?
The SURPASS clinical trial programme followed patients for up to 104 weeks (approximately 2 years), with ongoing extension studies continuing to monitor long-term safety. Post-marketing surveillance continues to monitor for any emerging safety signals.
Can Mounjaro reduce my cancer risk by helping me lose weight?
Obesity is an established risk factor for at least 13 cancer types. Whilst the substantial weight loss achieved with Mounjaro may theoretically reduce obesity-related cancer risk, dedicated long-term studies are needed to confirm any protective effects.
What should I do if I'm worried about cancer whilst taking Mounjaro?
Contact your GP if you experience concerning symptoms such as a neck lump, persistent hoarseness, difficulty swallowing, or unexplained weight loss. Your UK prescriber at Cured Pharmacy can also address specific concerns during treatment reviews.
Is Mounjaro safer than other weight loss injections regarding cancer risk?
All GLP-1 receptor agonists (including Mounjaro, Wegovy, and Saxenda) carry similar thyroid cancer warnings based on animal data. Human clinical trial evidence has not identified increased cancer risk with any of these medications when used as prescribed.
Does Mounjaro cause cancer according to UK studies?
Current UK and European regulatory reviews show no confirmed causal link between Mounjaro (tirzepatide) and cancer in humans. Clinical trials monitor long-term safety continuously, and Cured Pharmacy provides up-to-date safety information with every prescription.
Are there any cancer-related warnings for Mounjaro in the UK?
Mounjaro carries a warning about thyroid C-cell tumours observed in animal studies, though human relevance remains unclear. UK prescribers, including those at Cured Pharmacy, screen patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing.
Should I avoid Mounjaro if I have a family history of cancer?
A family history of most cancers does not automatically exclude Mounjaro use, but specific thyroid cancer types require caution. Cured Pharmacy's UK-registered prescribers review your full medical and family history during consultation to ensure Mounjaro is safe and appropriate for you.
How is Mounjaro monitored for cancer risk in the UK?
The MHRA continuously monitors post-market safety data for Mounjaro, including any potential cancer signals reported by patients and healthcare providers. Cured Pharmacy follows all UK regulatory guidance and encourages patients to report any unusual symptoms during treatment for ongoing safety surveillance.
Can I get the cheapest Mounjaro price if I need cancer risk screening?
Yes, Cured Pharmacy offers Mounjaro from £124.99 with full prescriber assessment included at no extra cost. Our UK clinicians evaluate cancer-related risk factors during your online consultation to ensure safe prescribing at the cheapest UK price available.
Does Mounjaro cause cancer or increase cancer risk in the UK?
There is no evidence that Mounjaro (tirzepatide) causes cancer in humans. Thyroid tumours were observed in rodent studies, but regulatory bodies including the MHRA have approved Mounjaro for UK use after thorough safety reviews. Cured Pharmacy provides full prescriber consultations to assess your individual risk factors before treatment.
Should I avoid Mounjaro if I have a family history of thyroid cancer?
Mounjaro is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). During your Cured Pharmacy consultation, your prescriber will review your full medical and family history to ensure Mounjaro is safe for you.
What cancer-related side effects should I watch for on Mounjaro in the UK?
While extremely rare, contact your prescriber immediately if you notice a lump in your neck, hoarseness, difficulty swallowing, or persistent throat discomfort. Cured Pharmacy's UK-registered clinicians monitor all patients throughout treatment and are available for any concerns about Mounjaro side effects.
How does Cured Pharmacy screen for cancer risks before prescribing Mounjaro?
Every Cured Pharmacy consultation includes a comprehensive health questionnaire covering personal and family cancer history, particularly thyroid conditions. Our UK-registered prescribers will only approve Mounjaro if it is clinically safe and appropriate for you, with ongoing monitoring throughout your treatment journey.
Are Mounjaro cancer side effects more common at higher doses in the UK?
The rodent thyroid tumour findings occurred across dose ranges in animal studies, not specifically at higher doses, and have not been observed in human clinical trials. Cured Pharmacy prescribers start all patients at 2.5mg and gradually titrate upwards, monitoring for any side effects at each dose level to ensure your safety.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.